Pharmacokinetics and metabolism of a new antitumor semisynthetic ether phospholipid, 14C-labeled plasmanyl-(N-acyl)ethanolamine, in mice bearing sarcoma Mc11
Jazyk angličtina Země Německo Médium print
Typ dokumentu srovnávací studie, časopisecké články
PubMed
7962042
DOI
10.1007/bf01245378
Knihovny.cz E-zdroje
- MeSH
- antitumorózní látky metabolismus farmakokinetika MeSH
- aplikace orální MeSH
- experimentální sarkom farmakoterapie metabolismus MeSH
- fosfatidylethanolaminy metabolismus farmakokinetika MeSH
- inbrední kmeny myší MeSH
- injekce intravenózní MeSH
- myši MeSH
- radioizotopy uhlíku MeSH
- tkáňová distribuce MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- 1-O-octadecyl-2-oleoyl-sn-glycero-3-phospho-(N-palmitoyl)ethanolamine MeSH Prohlížeč
- antitumorózní látky MeSH
- fosfatidylethanolaminy MeSH
- radioizotopy uhlíku MeSH
New natural and semisynthetic antitumor ether phospholipids PNAE and PNAE(s) [plasmanyl-(N-acyl)ethanolamines] and their selective antitumor activity in vivo have been described previously. We are now presenting the pharmacokinetics, in vivo metabolism and distribution of a [14C]PNAE(s) preparation (1-O-octadecyl-2-oleoyl-sn-glycero-3-phospho-(N-[U-14C]palmitoyl) ethanolamine in the intact or Mc11-tumor-bearing BDF1 mice. Only partial degradation (about 50%-60%) of [14C]PNAE(s) was observed in vivo 24 h after i.v. administration, as detected by TLC analysis of phospholipids extracted from the blood, liver, tumor and brain of animals. Pharmacokinetic curves of [14C]PNAE(s) and its metabolites were fitted with a two-compartment model (t alpha 1/2 = 2.5 h, t beta 1/2 = 61.6 h). After repeated i.v. doses of [14C]PNAE(s) (administered on days 1, 2, 3, 4, and 5) accumulation of [14C]PNAE(s) and lyso-[14C]PNAE(s) in tumor tissue was detected. High levels of [14C]PNAE(s) were also detected in the liver, lung and spleen of animals. After i.v. administration of [14C]PNAE(s) the ether phospholipid was also detected in the brain tissue. The parmacokinetic data indicate that repeated parenteral doses of PNAE(s) are necessary to attain therapeutic concentrations in tumor tissue. The very high accumulation of [14C]PNAE(s) in the liver of animals after repeated i.v. doses, and the absence of toxic side-effects in vivo indicate a possible clinical therapeutic use of PNAE(s), especially in the treatment of tumor metastases in liver as well as in the prophylaxis of liver metastases after surgical removal of primary tumors.
Zobrazit více v PubMed
Prog Biochem Pharmacol. 1988;22:118-31 PubMed
Lipids. 1987 Nov;22(11):925-6 PubMed
Anticancer Res. 1981;1(6):345-52 PubMed
Biochim Biophys Acta. 1978 Jul 25;530(1):47-55 PubMed
Cancer Res. 1990 Jun 1;50(11):3327-30 PubMed
Neoplasma. 1993;40(4):213-7 PubMed
Cancer Res. 1983 Feb;43(2):541-5 PubMed
Int J Cancer. 1993 Jan 2;53(1):124-30 PubMed
Cancer Res. 1970 Feb;30(2):309-11 PubMed
Oncology. 1984;41(2):140-5 PubMed
Exp Mol Pathol. 1989 Feb;50(1):69-83 PubMed
FEBS Lett. 1990 Jun 4;265(1-2):104-6 PubMed
Lipids. 1987 Nov;22(11):962-6 PubMed
J Biol Chem. 1964 Dec;239:4081-90 PubMed
Anticancer Res. 1982 Jan-Apr;2(1-2):95-100 PubMed
Arch Geschwulstforsch. 1981;51(4):349-53 PubMed
Lipids. 1987 Nov;22(11):824-30 PubMed
Neoplasma. 1986;33(2):187-205 PubMed
J Biol Chem. 1957 May;226(1):497-509 PubMed
Cancer Res. 1979 Nov;39(11):4681-6 PubMed
Blut. 1982 Feb;44(2):71-8 PubMed
Cancer Res. 1969 Jan;29(1):251-7 PubMed
